Glenmede Trust’s Boston Scientific BSX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $4.36M | Sell |
102,235
-19,333
| -16% | -$1.05M | 0.02% | 473 |
|
|
2026
Q1 | $7.63M | Buy |
121,568
+13,572
| +13% | +$1.09M | 0.04% | 390 |
|
|
2025
Q4 | $10.3M | Buy |
+107,996
| New | +$10.6M | 0.05% | 333 |
|
|
2025
Q1 | $2M | Buy |
19,819
+1,874
| +10% | +$189K | 0.01% | 555 |
|
|
2024
Q4 | $1.6M | Sell |
17,945
-2,518
| -12% | -$222K | 0.01% | 597 |
|
|
2024
Q3 | $1.71M | Buy |
20,463
+3,261
| +19% | +$257K | 0.01% | 600 |
|
|
2024
Q2 | $1.32M | Buy |
17,202
+1,062
| +7% | +$77.7K | 0.01% | 636 |
|
|
2024
Q1 | $1.11M | Buy |
16,140
+1,131
| +8% | +$72.7K | 0.01% | 685 |
|
|
2023
Q4 | $868K | Buy |
15,009
+4,567
| +44% | +$244K | ﹤0.01% | 732 |
|
|
2023
Q3 | $551K | Buy |
10,442
+1,123
| +12% | +$58.9K | ﹤0.01% | 815 |
|
|
2023
Q2 | $466K | Hold |
9,319
| – | – | ﹤0.01% | 851 |
|
|
2023
Q1 | $466K | Buy |
9,319
+923
| +11% | +$43.5K | ﹤0.01% | 856 |
|
|
2022
Q4 | $388K | Sell |
8,396
-659
| -7% | -$28.5K | ﹤0.01% | 904 |
|
|
2022
Q3 | $349K | Buy |
+9,055
| New | +$363K | ﹤0.01% | 907 |
|
|
2022
Q2 | – | Sell |
-6,199
| Closed | -$274K | – | 1298 |
|
|
2022
Q1 | $274K | Sell |
6,199
-978
| -14% | -$42.4K | ﹤0.01% | 1056 |
|
|
2021
Q4 | $304K | Buy |
7,177
+792
| +12% | +$33.3K | ﹤0.01% | 1047 |
|
|
2021
Q3 | $276K | Buy |
6,385
+31
| +0.5% | +$1.37K | ﹤0.01% | 1050 |
|
|
2021
Q2 | $270K | Sell |
6,354
-366
| -5% | -$15.4K | ﹤0.01% | 1059 |
|
|
2021
Q1 | $259K | Buy |
6,720
+874
| +15% | +$33.1K | ﹤0.01% | 1009 |
|
|
2020
Q4 | $209K | Sell |
5,846
-4,568
| -44% | -$165K | ﹤0.01% | 1047 |
|
|
2020
Q3 | $397K | Buy |
10,414
+320
| +3% | +$12.3K | ﹤0.01% | 853 |
|
|
2020
Q2 | $353K | Buy |
10,094
+4,583
| +83% | +$165K | ﹤0.01% | 857 |
|
|
2020
Q1 | $249K | Hold |
5,511
| – | – | ﹤0.01% | 1118 |
|
|
2019
Q4 | $249K | Sell |
5,511
-288
| -5% | -$12.1K | ﹤0.01% | 1118 |
|
|
2019
Q3 | $235 | Buy |
5,799
+1,065
| +22% | +$45.1K | ﹤0.01% | 1103 |
|
|
2019
Q2 | $202 | Sell |
4,734
-1,236
| -21% | -$47.5K | ﹤0.01% | 1154 |
|
|
2019
Q1 | $228 | Buy |
5,970
+52
| +0.9% | +$1.99K | ﹤0.01% | 1131 |
|
|
2018
Q4 | $208 | Buy |
+5,918
| New | +$215K | ﹤0.01% | 1102 |
|
|
2018
Q3 | – | Sell |
-3,952
| Closed | -$129K | – | 1489 |
|
|
2018
Q2 | $129K | Sell |
3,952
-20,238
| -84% | -$610K | ﹤0.01% | 1189 |
|
|
2018
Q1 | $598K | Hold |
24,190
| – | – | ﹤0.01% | 886 |
|
|
2017
Q4 | $598K | Sell |
24,190
-455
| -2% | -$12.5K | ﹤0.01% | 886 |
|
|
2017
Q3 | $718K | Sell |
24,645
-6,798
| -22% | -$188K | ﹤0.01% | 828 |
|
|
2017
Q2 | $781K | Hold |
31,443
| – | – | ﹤0.01% | 826 |
|
|
2017
Q1 | $781K | Sell |
31,443
-6,810
| -18% | -$166K | ﹤0.01% | 826 |
|
|
2016
Q4 | $826K | Sell |
38,253
-94
| -0.2% | -$2.05K | ﹤0.01% | 789 |
|
|
2016
Q3 | $911K | Sell |
38,347
-7,373
| -16% | -$176K | 0.01% | 766 |
|
|
2016
Q2 | $1.07M | Buy |
45,720
+3,898
| +9% | +$84.3K | 0.01% | 734 |
|
|
2016
Q1 | $786K | Hold |
41,822
| – | – | 0.01% | 793 |
|
|
2015
Q4 | $771K | Hold |
41,822
| – | – | 0.01% | 810 |
|
|
2015
Q3 | $686K | Sell |
41,822
-4,985
| -11% | -$85.2K | 0.01% | 806 |
|
|
2015
Q2 | $828K | Hold |
46,807
| – | – | 0.01% | 785 |
|
|
2015
Q1 | $830K | Sell |
46,807
-472
| -1% | -$7.46K | 0.01% | 812 |
|
|
2014
Q4 | $625K | Sell |
47,279
-24,645
| -34% | -$315K | ﹤0.01% | 839 |
|
|
2014
Q3 | $849K | Buy |
71,924
+15,089
| +27% | +$190K | 0.01% | 731 |
|
|
2014
Q2 | $725K | Sell |
56,835
-1,500
| -3% | -$19.5K | 0.01% | 766 |
|
|
2014
Q1 | $788K | Buy |
58,335
+4,600
| +9% | +$60.4K | 0.01% | 759 |
|
|
2013
Q4 | $645K | Hold |
53,735
| – | – | 0.01% | 786 |
|
|
2013
Q3 | $630K | Sell |
53,735
-185
| -0.3% | -$2K | 0.01% | 765 |
|
|
2013
Q2 | $499K | Buy |
+53,920
| New | +$457K | 0.01% | 784 |
|
Other funds holding BSX
Glenmede Trust's BSX Position: Q2 2026 in Review
Glenmede Trust reduced its Boston Scientific (BSX) stake by 16% in Q2 2026, selling an estimated $1.05M and leaving 102,235 shares worth $4.36M. The position accounts for 0.02% of the portfolio, ranked #473.
Glenmede Trust first reported a position in BSX in Q2 2013 and has held it in 49 quarters since. The position peaked at $10.3M in Q4 2025. 1,468 funds tracked by Wall St. Rank hold BSX as of Q2 2026.
- Glenmede Trust held 102,235 shares of Boston Scientific worth $4.36M as of Q2 2026.
- Glenmede Trust sold 19,333 Boston Scientific shares in Q2 2026, an estimated $1.05M.
- Boston Scientific made up 0.02% of Glenmede Trust's portfolio in Q2 2026, its #473 holding.
- Glenmede Trust first reported a position in Boston Scientific in Q2 2013 and has held it in 49 quarters since.
- Glenmede Trust's Boston Scientific position peaked at $10.3M in Q4 2025.
- 1,468 funds tracked by Wall St. Rank held Boston Scientific as of Q2 2026.
Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.